Trimethylamine N-oxide, a gut microbiota-dependent metabolite in Chronic Hepatitis B DOI Creative Commons
Esra Paydaş Hataysal, Muslu Kazım Körez, Nuray Heydar Kasar

et al.

Genel Tıp Dergisi, Journal Year: 2024, Volume and Issue: 34(6), P. 853 - 860

Published: Dec. 30, 2024

Background: Trimethylamine N-oxide (TMAO), a gut microbiota metabolite is produced in the liver from dietary precursors such as choline, betaine, and L-carnitine. TMAO has been linked to inflammatory processes oxidative stress, both of which are critical factors progression hepatitis. This article aims examine impact on Chronic hepatitis B (CHB). Materials Methods: The study included 41 treatment-naïve CHB patients with HBV DNA levels above 2000 IU/mL, well 46 age gender-matched controls. Serum were measured using Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS). All statistical analysis was performed R version 4.2.1. Results: Patients have more significant increase serum level than healthy controls (1860 [IQR, 808 – 2720] vs. 552.5 252 876.5], p<0.001). ALT AST higher (p<0.001 positively correlated (r=0.466, p<0.001; r=0.376, p<0.001) had predictive power for an area under curve 0.808. Conclusions: Our results indicate that there link between TMAO, microbiota-dependent metabolite, disease. Since synthesized mainly liver, its raised may be associated liver-related diseases.

Language: Английский

NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options DOI Creative Commons
Natalia G. Vallianou, Dimitris Kounatidis,

Sotiria Psallida

et al.

Metabolites, Journal Year: 2024, Volume and Issue: 14(7), P. 366 - 366

Published: June 28, 2024

Nonalcoholic fatty liver disease (NAFLD) poses an emerging threat topublic health. steatohepatitis (NASH) is reported to be the most rapidly rising cause of hepatocellular carcinoma in western world. Recently, a new term has been proposed: metabolic dysfunction-associated steatotic (MASLD). The introduction this terminology sparked debate about interchangeability these terms. pathogenesis NAFLD/MASLD thought multifactorial, involving both genetic and environmental factors. Among factors, alterations gut microbiota dysbiosis have recently garnered significant attention. In context, review will further discuss gut-liver axis, which refers bidirectional interaction between human liver. Additionally, therapeutic potential probiotics, particularly next-generation probiotics genetically engineered bacteria, explored. Moreover, role prebiotics, synbiotics, postbiotics, phages as well fecal transplantation analyzed. Particularly for lean patients with NAFLD/MASLD, who limited treatment options, approaches that modify diversity composition may hold promise. However, due ongoing safety concerns modulate microbiota, large-scale studies are necessary better assess their efficacy treating NAFLD/MASLD.

Language: Английский

Citations

25
Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD DOI Creative Commons
Fabrizio Termite,

Sebastiano Archilei,

Francesca D’Ambrosio

et al.

Antioxidants, Journal Year: 2025, Volume and Issue: 14(1), P. 56 - 56

Published: Jan. 6, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic condition marked by excessive lipid accumulation in hepatic tissue. This disorder can lead to range of pathological outcomes, including metabolic steatohepatitis (MASH) and cirrhosis. Despite extensive research, the molecular mechanisms driving MASLD initiation progression remain incompletely understood. Oxidative stress peroxidation are pivotal "multiple parallel hit model", contributing cell death tissue damage. Gut microbiota plays substantial role modulating oxidative through multiple pathways: impairing intestinal barrier, which results bacterial translocation inflammation; modifying bile acid structure, impacts signaling cascades involved lipidic metabolism; influencing hepatocytes' ferroptosis, form programmed death; regulating trimethylamine N-oxide (TMAO) activating platelet function, both recently identified as pathogenetic factors MASH progression. Moreover, various exogenous impact gut its involvement MASLD-related stress, such air pollution, physical activity, cigarette smoke, alcohol, dietary patterns. manuscript aims provide state-of-the-art overview focused on intricate interplay between microbiota, peroxidation, pathogenesis, offering insights into potential strategies prevent associated complications.

Language: Английский

Citations

2
Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease DOI Creative Commons
Emidio Scarpellini, Marialaura Scarcella, Jan Tack

et al.

Antioxidants, Journal Year: 2024, Volume and Issue: 13(11), P. 1386 - 1386

Published: Nov. 14, 2024

Background: The gut microbiota constitutes a complex microorganism community that harbors bacteria, viruses, fungi, protozoa, and archaea. human bacterial has been extensively proven to participate in metabolism, immunity, nutrient absorption. Its imbalance, namely “dysbiosis”, linked disordered metabolism. Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the features deranged metabolism leading cause cirrhosis hepatocellular carcinoma. Thus, there pathophysiological link between dysbiosis MASLD. Aims Methods: We aimed review literature data on composition its MASLD describe concept “gut–liver axis”. Moreover, we reviewed approaches for modulation treatment. Results: There consolidated evidence particular associated with stages. model explaining relationship bidirectional organization, physiopathology Oxidative stress keystones pathophysiology fibrosis generation. promising efficacy pre- probiotics reversing patients, therapeutic effects. Few yet encouraging fecal transplantation (FMT) are available literature. Conclusions: characteristic key target reversal treatment via diet, pre/probiotics, FMT remains treatment, prevention, reversal.

Language: Английский

Citations

4
Factors responsible for alpha-Synuclein aggregation DOI

Khuraijam Surjalal Singh,

Rahul Verma,

N. Okendro Singh

et al.

Progress in molecular biology and translational science, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
A Cascade of Microbiota-Leaky Gut-Inflammation- Is it a Key Player in Metabolic Disorders? DOI
Sidharth Mishra,

Shalini Jain,

Bryan Agadzi

et al.

Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)

Published: April 10, 2025

Language: Английский

Citations

0
Inverse associations between Mediterranean diet constituents and the gut microbiota in metabolic-associated steatotic liver disease (MASLD): a case-control study DOI
Georgina M. Williams, Emily C. Hoedt, Kerith Duncanson

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: April 21, 2025

Abstract Background Dietary therapy, specifically for weight loss, is currently considered first-line therapy metabolic-associated steatotic liver disease (MASLD). However, increasing recognition of the role gut-liver axis in MASLD highlights potential microbiota-modulating dietary to improve outcomes. This study aimed explore variables relevant gut microbiota MASLD. Methods Twenty-five adults with and 25 healthy controls were recruited using a retrospective case-control design characterised 3-day intake records, clinical markers, shotgun metagenomic sequencing. Results participants consumed less fibre (p = < 0.01), very long chain omega-3 fatty acids 0.02), nuts seeds 0.03), whole grains 0.01) vegetables 0.04). Participants had lower abundance Alistipes senegalensis (r=-0.01, p 0.04), Coprococcus eutactus (r=-0.07, 0.006), Faecalibacterium (r=-0.02, 0.001), higher Ruminococcus torques (r 0.04, expression functional pathways associated ethanol production, methionine, folate branched-chain amino acid metabolism. Bacterial species more abundant positively added sugars saturated fat, negatively unsaturated intake. Conclusions Microbiota characteristics differ between individuals without MASLD, this influenced by Future translation-focused research investigating interventions gut-liver-axis are warranted.

Language: Английский

Citations

0
SINTESIS SENYAWA METABOLIT OLEH MIKROBIOTA SALURAN CERNA DAN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): TINJAUAN PADA SCFA DAN BCAA DOI Open Access

Hainun Zariyah,

Adriyan Pramono

Journal of Nutrition College, Journal Year: 2025, Volume and Issue: 14(2), P. 136 - 155

Published: Jan. 2, 2025

ABSTRACTMetabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty (NAFLD), affects more than one-third of the adult population and over ten percent children. The global prevalence MASLD is estimated to range from 32% 37.3%, with higher in men individuals obesity. pathophysiology highly complex, starting excessive lipid accumulation liver, oxidative stress, mitochondrial dysfunction, ending disruptions gut-microbiota-liver axis. In last decade, gastrointestinal microbiota has been recognized a major regulator energy homeostasis metabolism, imbalance affecting adipose tissue, muscle. Components metabolites, such short-chain acids (SCFA) branched-chain amino (BCAA), play crucial role gut-host-microbiome metabolic axis development MASLD. This review discusses relationship between microbiota-related metabolites detected through metabolomics, well potential SCFAs BCAAs biomarkers for early detection MASLD.Keyword : Microbiota; metabolite; (MASLD); (SCFA); (BCAA) ABSTRAKMetabolic sebelumnya dikenal sebagai mempengaruhi lebih dari sepertiga populasi dewasa dan sepuluh persen anak-anak. Prevalensi diperkirakan mencapai hingga 37,3% secara global, dengan prevalensi yang tinggi pada laki-laki individu obesitas. Patofisiologi sangat kompleks, dimulai akumulasi berlebihan di hati, stres oksidatif, disfungsi mitokondria, berakhir gangguan microbiota-gut-liver-axis. Dalam 10 tahun terakhir, mikrobiota saluran cerna telah dikenali pengatur utama energi metabolisme, ketidakseimbangan metabolisme jaringan adiposa, otot. Komponen metabolit mikrobiota, seperti asam lemak rantai pendek atau acid cabang berperan penting dalam jalur gut host-microbiome perkembangan Ulasan ini membahas hubungan antara terkait terdeteksi melalui metabolomik, serta peran SCFA BCAA biomarker potensial deteksi dini MASLD.Kata kunci Mikrobiota; metabolit;

Language: Английский

Citations

0
Deciphering the Gut–Liver Axis: A Comprehensive Scientific Review of Non-Alcoholic Fatty Liver Disease DOI Creative Commons
Samradhi Singh, Mona Kriti, Roberto Catanzaro

et al.

Livers, Journal Year: 2024, Volume and Issue: 4(3), P. 435 - 454

Published: Sept. 12, 2024

Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant global health issue. The condition is closely linked to metabolic dysfunctions such obesity and type 2 diabetes. gut–liver axis, bidirectional communication pathway between the gut, plays crucial role in pathogenesis of NAFLD. This review delves into mechanisms underlying exploring influence gut microbiota, intestinal permeability, inflammatory pathways. also explores potential therapeutic strategies centered on modulating microbiota fecal transplantation; phage therapy; use specific probiotics, prebiotics, postbiotics managing By understanding these interactions, we can better comprehend development advancement NAFLD identify targets.

Language: Английский

Citations

0
MASHing up molecular imaging and biomarkers for improved diagnosis of metabolic dysfunction-associated steatotic liver disease DOI
Sharmila Fagoonee, Riccardo Panella

Minerva Biotechnology and Biomolecular Research, Journal Year: 2024, Volume and Issue: 36(4)

Published: Dec. 1, 2024

Language: Английский

Citations

0
Trimethylamine N-oxide, a gut microbiota-dependent metabolite in Chronic Hepatitis B DOI Creative Commons
Esra Paydaş Hataysal, Muslu Kazım Körez, Nuray Heydar Kasar

et al.

Genel Tıp Dergisi, Journal Year: 2024, Volume and Issue: 34(6), P. 853 - 860

Published: Dec. 30, 2024

Background: Trimethylamine N-oxide (TMAO), a gut microbiota metabolite is produced in the liver from dietary precursors such as choline, betaine, and L-carnitine. TMAO has been linked to inflammatory processes oxidative stress, both of which are critical factors progression hepatitis. This article aims examine impact on Chronic hepatitis B (CHB). Materials Methods: The study included 41 treatment-naïve CHB patients with HBV DNA levels above 2000 IU/mL, well 46 age gender-matched controls. Serum were measured using Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS). All statistical analysis was performed R version 4.2.1. Results: Patients have more significant increase serum level than healthy controls (1860 [IQR, 808 – 2720] vs. 552.5 252 876.5], p&lt;0.001). ALT AST higher (p&lt;0.001 positively correlated (r=0.466, p&lt;0.001; r=0.376, p&lt;0.001) had predictive power for an area under curve 0.808. Conclusions: Our results indicate that there link between TMAO, microbiota-dependent metabolite, disease. Since synthesized mainly liver, its raised may be associated liver-related diseases.

Language: Английский

Citations

0